Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 12/20 | 0.44 |
| ▸ | FLT3 | P36888 | 4/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12049378 | 0.94 | CSF1R (0.51) | CSF1RPDGFRBFLT3PDGFRAKIT | |
| SCHEMBL12049294 | 0.93 | NAMPT (0.46) | NAMPTMAPTMEN1KMT2APDGFRB | |
| SCHEMBL12049347 | 0.93 | CSF1R (0.50) | CSF1RPDGFRBFLT3PDGFRAKIT | |
| SCHEMBL12049323 | 0.92 | CSF1R (0.47) | CSF1RHRH3PDGFRBFLT3PDGFRA | |
| SCHEMBL5074971 | 0.91 | PDGFRB (0.46) | MAPTCSF1RPDGFRBFLT3PDGFRA | |
| SCHEMBL4962338 | 0.91 | CSF1R (0.44) | CSF1RPDGFRBFLT3PDGFRAKIT | |
| SCHEMBL12049433 | 0.90 | TRPV1 (0.49) | NAMPTCSF1RPDGFRBFLT3PDGFRA | |
| SCHEMBL12049410 | 0.90 | CSF1R (0.45) | MAPTCSF1RPDGFRBFLT3 | |
| SCHEMBL12049445 | 0.90 | CSF1R (0.45) | NAMPTCSF1RPDGFRBFLT3PDGFRA | |
| SCHEMBL12060706 | 0.89 | PRKDC (0.53) | CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | FLT3, MCL1, CDC42BPG | NAMPT 1570/4885MAPT 4814/4885CSF1R 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.